Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients
Completed
- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer
- Registration Number
- NCT06452212
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Brief Summary
The purpose of this study is to establish an expert consensus recommendations on managing patients with mHSPC in South Korea, and to provide clinicians with a comprehensive guide to support their clinical decision making. There are no secondary objectives for this study.
- Detailed Description
Data collection for this study will be conducted through 2 rounds of web-based surveys of health care professionals (HCPs). A meeting with the panelists will be held as a 3rd round if a consensus for pre determined key questions is not achieved after the 2 rounds of the survey.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
- Urologist from university hospitals in South Korea.
- Has a minimum 10 years of practice experience (experience as a military or public health doctor could be considered practice experience)
- Sees a minimum of 50 mHSPC patients in a year.
- At least 10 publications in SCIE (Science Citation Index Expanded) journals in the past 5 years.
Exclusion Criteria
- Urologist in private practice.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment plans for patients with mHSPC Up to 7 days Treatment plans for patients with mHSPC within the local healthcare environment will be collected via online surveys and a consensus meeting will be held if required.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
KR82001
🇰🇷Seoul, Korea, Republic of
KR82001🇰🇷Seoul, Korea, Republic of